Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) EBIT (2020 - 2025)

Xeris Biopharma Holdings' EBIT history spans 6 years, with the latest figure at $16.8 million for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 898.99% year-over-year to $16.8 million, compared with a TTM value of $24.9 million through Dec 2025, up 173.99%, and an annual FY2025 reading of $24.9 million, up 173.99% over the prior year.
  • EBIT for Q4 2025 was $16.8 million at Xeris Biopharma Holdings, up from $6.7 million in the prior quarter.
  • The five-year high for EBIT was $16.8 million in Q4 2025, with the low at -$48.3 million in Q4 2021.
  • Average EBIT over 5 years is -$12.5 million, with a median of -$13.8 million recorded in 2023.
  • Year-over-year, EBIT plummeted 162.43% in 2024 and then surged 898.99% in 2025.
  • Tracing XERS's EBIT over 5 years: stood at -$48.3 million in 2021, then soared by 68.57% to -$15.2 million in 2022, then skyrocketed by 35.13% to -$9.8 million in 2023, then soared by 117.06% to $1.7 million in 2024, then surged by 898.99% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's EBIT are $16.8 million (Q4 2025), $6.7 million (Q3 2025), and $4.5 million (Q2 2025).